| Bid | 0.54 |
| Market Cap | 29.91M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.47 |
| PE Ratio (ttm) | -0.22 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 0.54 |
| Volume | 1,032,380 |
| Avg. Volume (20D) | 3,515,034 |
| Open | 0.54 |
| Previous Close | 0.54 |
| Day's Range | 0.54 - 0.54 |
| 52-Week Range | 0.22 - 10.50 |
| Beta | undefined |
About MRNS
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The...
Analyst Forecast
According to 12 analyst ratings, the average rating for MRNS stock is "Hold." The 12-month stock price forecast is $2.5, which is an increase of 361.60% from the latest price.
Next Earnings Release
Analysts project revenue of $10.59M, reflecting a 47.29% YoY growth and earnings per share of -0.35, making a -52.70% decrease YoY.
2 weeks ago · businesswire.com
Immedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc.STOCKHOLM & RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Immedica Pharma AB (Immedica), a leading global rare disease company, and Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceuti...
